Sustainability and affordability of cancer drugs: a novel pricing model

Affiliations

¹ Erasmus School of Health Policy & Management and Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, Netherlands. uyl@eshpm.eur.nl.
² Department of Haematology, Erasmus University Medical Center, Rotterdam, Netherlands.

Comment

Carin A Uyl-de Groot et al. Nat Rev Clin Oncol. 2018 Jul.

. 2018 Jul;15(7):405-406.

doi: 10.1038/s41571-018-0027-x.

¹ Erasmus School of Health Policy & Management and Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, Netherlands. uyl@eshpm.eur.nl.
² Department of Haematology, Erasmus University Medical Center, Rotterdam, Netherlands.

No abstract available

Comment in

Response to proposal for a novel cancer drug pricing model.
van der Gronde T, Leufkens HG, Pieters T. van der Gronde T, et al. Nat Rev Clin Oncol. 2018 Aug;15(8):528. doi: 10.1038/s41571-018-0062-7. Nat Rev Clin Oncol. 2018. PMID: 29955112 No abstract available.
Economic comments on proposal for a novel cancer drug pricing model.
Nuijten MJC, Vis J. Nuijten MJC, et al. Nat Rev Clin Oncol. 2018 Sep;15(9):587. doi: 10.1038/s41571-018-0083-2. Nat Rev Clin Oncol. 2018. PMID: 30104696 No abstract available.

Reply to 'Response to proposal for a novel cancer drug pricing model'.
Uyl-de Groot CA, Löwenberg B. Uyl-de Groot CA, et al. Nat Rev Clin Oncol. 2018 Aug;15(8):528-529. doi: 10.1038/s41571-018-0063-6. Nat Rev Clin Oncol. 2018. PMID: 29955113 No abstract available.
Reply to 'Economic comments on proposal for a novel cancer drug pricing model'.
Uyl-de Groot CA, Löwenberg B. Uyl-de Groot CA, et al. Nat Rev Clin Oncol. 2018 Sep;15(9):588. doi: 10.1038/s41571-018-0084-1. Nat Rev Clin Oncol. 2018. PMID: 30104695 No abstract available.